Test Research Inc (3030) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Test Research Inc stock TWD 221, price TWD 201, upside +10.0%, quality 79 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 47.56 TWD – 419.50 TWD · fair‑value band 120.12 TWD – 325.34 TWD · the 201.00 TWD price screens below the 221.10 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Test Research in your weekly email
Every Wednesday you see whether Test Research is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Test Research, Inc., together with its subsidiaries, engages in the design, assembly, manufacturing, sales, and repair of automated inspection and testing equipment in Asia, the Americas, Europe, and internationally.
Show moreShow less
The company offers optical inspection solutions, including 3D solder paste inspection; automated optical inspection; conformal coating inspection; and automated x-ray inspection.
It also provides electrical test, such as manufacturing defects analyzer and in-circuit tester; and optical and x-ray inspection solutions. Test Research, Inc. was founded in 1978 and is headquartered in Taipei, Taiwan.
Stock analysis
Test Research Inc (3030) currently trades at 201.00 TWD, while our model-based Fair Value estimate is 221.10 TWD, so the stock looks roughly fairly valued today (gap 9.1%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 232.93 TWD per share, and 9 of the 26 models we run sit above the 201.00 TWD price.
Bear case: the Dividend Discount group reads lowest at 72.85 TWD, and 17 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 120.12 TWD (bear) to 325.34 TWD (bull), the price of 201.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 79/100 (high quality), in the Technology sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Test Research Inc reported revenue of 8.5B TWD in FY2025 versus 5.6B TWD in FY2021, a compound +10.9%/yr. Reported net income was 2.5B TWD in FY2025, compounding +20.3%/yr from FY2021.
Key figures
Market cap 61.2B TWD (≈ $1.9B) Small · P/E ratio 15.3 · P/S ratio 6.42 · EPS (TTM) 13.18 TWD · Dividend yield 3.5% · Net margin 32.7% · Return on equity 35.0% · Return on assets (EBIT) 20.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 93 out of 100 (medium confidence).
What moves the price
The share trades about 52% below its 52-week high and 41% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −45% fair-value upside, at 10%, 3030 screens cheaper than that median.
Fair Value models
Bear120.12 TWDFair Value 221.10 TWDBull325.34 TWD
Price 201.00 TWD · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (5.28 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.94/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+33.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Start year 2020 (pandemic). Over 10 years: +5.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+21.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.8%
Dividend (yield on the price)3.5%
Per share before 2013divided by the spin-off factor 1.06
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.17.8% vs 9.6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 35%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +18.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Scientific & Technical Instruments · 161 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Test Research Inc Fair Value". https://www.fairvalue-calculator.com/stock/3030
Frequently asked questions
Is Test Research Inc (3030) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 221.10 TWD versus a price of 201.00 TWD, about +10% upside (fairly valued).
What is the fair value of 3030?
Our model-based fair value for Test Research Inc is 221.10 TWD (as of Nov 7, 2026), built from audited fundamentals. The current price: 201.00 TWD.
What is the quality score of 3030?
Test Research Inc has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Test Research Inc (3030)?
Our model-based price target is the fair value of 221.10 TWD (as of Nov 7, 2026) from 26 valuation models. Cautious scenario 120.12 TWD, optimistic scenario 325.34 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Test Research Inc stock forecast for 2026?
Our models put fair value at 221.10 TWD, about +10% upside versus a price of 201.00 TWD (fairly valued). Cautious scenario 120.12 TWD, optimistic scenario 325.34 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Test Research Inc (3030)?
Test Research Inc reported trailing-twelve-month revenue of about 9.5B TWD (latest available figure, as of Nov 7, 2026).
Does Test Research Inc pay a dividend?
Test Research Inc currently shows a dividend yield of 3.48% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Test Research Inc (3030) and when is the ex-dividend date?
Test Research Inc pays a dividend of 7.00 TWD per share a year, a dividend yield of 3.5%. The last ex-dividend date was Jun 11, 2026. The payout ratio is 53.1% of earnings. Free cash flow covers the dividend 0.87 times. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What growth is priced into Test Research Inc (3030)?
For today's price to be fair in a discounted-cash-flow model, Test Research Inc would have to grow free cash flow by +20.1 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.3 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 3030 use?
Our models discount Test Research Inc at 10.3 %: a base by market capitalisation (small), damped by beta 0.51, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Test Research Inc that is +20.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Test Research Inc (3030) delivered so far?
Over the past 5 years revenue at Test Research Inc grew +11.3 % a year. The price currently implies free-cash-flow growth of +20.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Test Research Inc (3030) growing?
The median revenue growth in the sector is +11.5 % a year. That is the yardstick for the growth priced into Test Research Inc (+20.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Test Research Inc (3030)?
The free-cash-flow yield on the price is 3.02 %: that much free cash flow Test Research Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Test Research Inc (3030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Test Research Inc it is 221.10 TWD per share (as of Nov 7, 2026), against a price of 201.00 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Test Research Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 3030 trades below its calculated fair value: price 201.00 TWD, fair value 221.10 TWD, a gap of about +10% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3030?
No. The price is what the market pays today (201.00 TWD); the fair value is what the company's own numbers justify (221.10 TWD). For Test Research Inc the two are 20.10 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Test Research Inc worth?
The market values Test Research Inc at about 61.2B TWD (market capitalisation, as of Nov 7, 2026). Per share that is 201.00 TWD; our models calculate a fair value of 221.10 TWD per share.
What do the bullish and bearish scenarios say about 3030?
Our models span a range for Test Research Inc: cautious scenario 120.12 TWD, base 221.10 TWD, optimistic 325.34 TWD per share (as of Nov 7, 2026, price 201.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 3030?
Test Research Inc trades at a price-to-earnings ratio of 15.3 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 221.10 TWD is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 14.1. Other multiples: PEG 16.0, P/B 6.4, P/S 6.4, EV/EBITDA 16.5.
What is the PEG ratio of 3030?
The PEG ratio of Test Research Inc is 15.98 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Test Research Inc (3030)?
Balance-sheet figures for Test Research Inc (as of Nov 7, 2026): return on equity 35.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is 3030 from its 52-week high?
Test Research Inc trades at 201.00 TWD, about 52% below its 52-week high of 419.50 TWD and 41% above the low of 142.50 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 221.10 TWD is for.
Which stocks are comparable to Test Research Inc?
From the same area (Technology) we also value Keysight Technologies, Inc, Garmin Ltd, Coherent Corp, Teledyne Technologies Incorporated, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Test Research Inc stock attractive at the current price?
The data as of Nov 7, 2026: price 201.00 TWD, calculated fair value 221.10 TWD (+10%), Quality Score 79/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3030 calculated?
We run Test Research Inc through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 221.10 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Test Research Inc currently trades 9% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Test Research Inc (3030)?
The closing price on Nov 6, 2026 was 201.00 TWD. Our model-based fair value is 221.10 TWD, about +10% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Test Research Inc right now?
The model range is unusually wide (120.12 TWD to 325.34 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Where does the earnings growth of Test Research Inc (3030) come from?
Earnings per share at Test Research Inc grew +7.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.9 %, EBIT margin +4.3 %, tax rate +0.0 %, residual (interest, one-offs) −0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Test Research Inc
How large is the market capitalisation of Test Research Inc (3030)?
The market capitalisation of Test Research Inc is 61.2B TWD (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Test Research Inc (3030)?
The price-to-sales ratio of Test Research Inc is 6.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Test Research Inc (3030)?
Earnings per share at Test Research Inc are 13.18 TWD (price ÷ EPS = P/E 15.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Test Research Inc (3030)?
The dividend yield of Test Research Inc is 3.5% (payout 53.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Test Research Inc (3030)?
The net margin of Test Research Inc is 32.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Test Research Inc (3030)?
The return on equity (ROE) of Test Research Inc is 35.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Test Research Inc (3030)?
On an EBIT basis the return on assets of Test Research Inc is 20.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Test Research Inc (3030)?
The operating margin of Test Research Inc is 39.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Test Research Inc (3030)?
Revenue at Test Research Inc is growing +23.9% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Test Research Inc (3030)?
Earnings per share at Test Research Inc are growing +74.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Test Research Inc (3030) hold?
Test Research Inc holds more cash than debt, 1.2B TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Test Research Inc in the live analysis
One click puts Test Research Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 7, 2026